InCROM has been supporting clinical trials in patients since 1993. Over the past 30 years, we have accumulated a wealth of experience, especially in lifestyle-related diseases, allergic rhinitis, bronchial asthma, atopic dermatitis, knee osteoarthritis, glaucoma, and dry eye. Together with our vast subjects panel, we are highly proficient in providing recruitment forecast and information relevant to the study planning.
We are also able to meet different client requirements with a high level of flexibility, e.g. electromagnetic transfer of materials, remote SDV, RBM, central IRB, etc., in order to provide more client-oriented services.
Indications InCROM specializes in and the corresponding number of registered subjects (as of June 1, 2025)
Seasonal Allergic Rhinitis: 20,146
Perennial Allergic Rhinitis 8,845
Dyslipidemia: 17,808
Hypertension: 20,072
Diabetes: 11,718
Dry Eye: 5,912
Hyperuricemia: 2,594
Atopic Dermatitis: 8,687
Bronchial Asthma: 7,321
Lower Back Pain: 1,647
Knee Osteoarthritis: 1,453
Glaucoma: 3,420
Clinical trials recruitment systematically facilitated by the subjects panel consisting of over 450,000 registrants
1. Clinical Symptoms Questionnaires
For certain indications (examples below), a large number of patients are undiagnosed and/or untreated. Questionnaires designed to identify patients by asking about relevant clinical symptoms are sent to the panel registrants, and the result of which translates to high-speed, large candidates pool identification.
Examples of target indications: urinary incontinence, allergic rhinitis, dry eye, asthenopia, insomnia, MCI (mild cognitive impairment)
2. Advance Candidates Identification Through Visual Data
For certain indications (examples below), study feasibility is effectively achieved by obtaining photographs of the specific anatomical locations from the potential candidates registered on the panel. This allows for quick and high precision forecast on the appropriate number of patients.
Examples of target indications: androgenetic alopecia, nail tinea, atopic dermatitis
3. Proactive Candidates Preparation
For certain indications (examples below), matching candidate identification can also lead to the need for immediate treatment. To enhance maximal recruitment in sync with the study timeline, potential candidates are primed proactively.
Examples of target indications: influenza syndrome, cold syndrome
Regulatory approvals in the past 5 years for which the patient studies were supported by InCROM
2024: Insomnia agent (Dual orexin receptor antagonist)
2024: Conjunctival hyperaemia agent (α2AR agonist)
2023: Dyslipidaemia agent (PCSK9 Inhibitor)
2023: Dyslipidaemia agent (Selective PPRAα Modulator)
2022: Obesity agent (GLP-1 receptor agonist)
2022: Glaucoma agent (Rho kinase inhibitor / Alpha 2 agonist)
2022: Hypercholesterolemia agent (HMG-CoA reductase inhibitors / Small intestinal cholesterol transporter inhibitor)
2021: Hypoferric anemia agent (Ferric citrate)
2020: Bronchial asthma agent (Steroid / Beta 2 stimulant)
2020: Type 2 diabetes agent (GLP-1 receptor agonist)
2020: Glaucoma agent (Alpha 2 stimulant / Carbonic anhydrase inhibitor)
2020: Type 2 diabetes agent (Insulin / GLP-1 receptor agonist)
